Treatment of neuropsychiatric syndromes in multiple sclerosis

References

• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). American Psychiatric Association, Washington, DC, USA (2000).
   Google Scholar
• Katon WJ, Von Korff M, Lin EHB et al. The Pathways study. Arch. Gen. Psychiatry 61, 1042–1049 (2004).
   PubMed Web of Science ®Google Scholar
• Joffe RT, Lippert GP, Gray TA, Sawa G, Horvath Z. Mood disorders and multiple sclerosis. Arch. Neurol. 44, 376–378 (1987).
   PubMed Web of Science ®Google Scholar
• Minden SL, Orav J, Reich P. Depression in multiple sclerosis. Gen. Hosp. Psychiatry 9, 426–434 (1987).
   PubMed Web of Science ®Google Scholar
• Patten SB, Metz LM, Reimer MA. Biopsychosocial correlates of major depression in a multiple sclerosis population. Mult. Scler. 6, 115–120 (2000).
   PubMed Web of Science ®Google Scholar
• Patten SB, Beck CA, Williams JVA, Barbui C, Metz L. Major depression in multiple sclerosis: a population-based perspective. Neurology 61, 1524–1527 (2003).
   PubMed Web of Science ®Google Scholar
• Aikens JE, Reinecke MA, Pliskin NH et al. Assessing depressive symptoms in multiple sclerosis: is it necessary to omit items from the original Beck Derpession Inventory? J. Behav. Med. 22, 127–141 (1999).
   PubMed Web of Science ®Google Scholar
• Nyenhuis DL, Rao SM, Zajecka JM et al. Mood disturbance versus other symptoms of depression in multiple sclerosis. J. Internatl Neuropsychol. Soc. 1, 291–296 (1995).
   PubMedGoogle Scholar
• Schiffer RB, Wineman NM. Antidepressant pharmacotherapy of depression associated with multiple sclerosis. Am. J. Psychiatry 147, 1493–7 (1990).
   PubMed Web of Science ®Google Scholar
• Mohr DC, Boudewyn AC, Goodkin DE, Bostrom A, Epstein L. Comparative outcomes for individual cognitive–behavior therapy, supportive-expressive group psychotherapy, and sertraline for the treatment of depression in multiple sclerosis. J. Cons. Clin. Psychol. 69, 942–949 (2001).
   PubMed Web of Science ®Google Scholar
• Scott TF, Nussbaum P, McConnell H, Brill P. Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carrol scale. Neurol. Res. 17, 421–422 (1995).
   PubMed Web of Science ®Google Scholar
• Barak Y, Ur E, Achiron A. Moclobemide treatment in multiple sclerosis patients with comorbid depression: an open-label safety trial. J. Neuropsych. Clin. Neurosci. 11, 271–273 (1999).
   PubMed Web of Science ®Google Scholar
• Stenager EN, Stenager E, Koch-Henriksen N et al. Suicide and multiple sclerosis: an epidemiological investigation. J. Neurol. Neurosurg. Psychiatry 55, 542–545 (1992).
   PubMed Web of Science ®Google Scholar
• Marrs RW. A meta-analysis of bibliotherapy studies. Am. J. Comm. Psychol. 23, 843–870 (1995).
   PubMed Web of Science ®Google Scholar
• Christensen H, Griffiths KM, Jorm AF. Delivering interventions for depression by using the internet: randomised controlled trial. BMJ 328, 265 (2004).
   Google Scholar
• Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dosage. Clin. Pharm. Ther. 13, 694–698 (1972).
   PubMed Web of Science ®Google Scholar
• Fishman SM, Catarau EM, Sachs GM, Stojanovic M, Borsook D. Corticosteroid-induced mania after single regional application at the celiac plexus. Anesthiology 85, 1194–1196 (1996).
   PubMed Web of Science ®Google Scholar
• Vincent FM. The neuropsychiatric complications of corticosteroid therapy. Comp. Ther. 21, 524–528 (1995).
   PubMedGoogle Scholar
• Rundell JR, Wise MG. Causes of organic mood disorder. J. Neuropsychiatry Clin. Neurosci. 1, 398–400 (1989).
   PubMedGoogle Scholar
• Waraich PS, Goldner EM, Somers JM, Hsu L. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can. J. Psychiatry 49, 124–38 (2004).
   PubMed Web of Science ®Google Scholar
• Feinstein A, Feinstein K. Depression associated with multiple sclerosis – looking beyond diagnosis to symptom expression. J. Affect. Disord. 66, 193–198 (2001).
   PubMed Web of Science ®Google Scholar
• Finger S. A happy state of mind. A history of mild elation, denial of disability, optimism, and laughing in multiple sclerosis. Arch. Neurol. 55, 241–250 (1998).
   PubMed Web of Science ®Google Scholar
• Feinstein A. Clinical Neuropsychiatry of Multiple Sclerosis. Cambridge University Press, UK (1999).
   Google Scholar
• Feinstein A, Feinstein K, Gray T, O’Connor P. The prevalence and neurobehavioural correlates of pathological laughter and crying in multiple sclerosis. Arch. Neurol. 54, 1116–1121 (1997).
   PubMed Web of Science ®Google Scholar
• Schiffer RB, Herndon RM, Rudick RA. Treatment of pathological laughing and weeping with amitriptyline. N. Engl. J. Med. 312, 1480–1482 (1985).
   PubMed Web of Science ®Google Scholar
• Udaka F, Yameo S, Nagata H, Nakamura S, Kameyama M. Pathological laughing and crying treated with levodopa. Arch. Neurol. 41, 1095–1096 (1984).
   PubMed Web of Science ®Google Scholar
• Nahas Z, Arlinghaus KA, Kotrla KJ, Clearman RR, George MS. Rapid response of emotional incontinence to selective serotonin re-uptake inhibitors. J. Neuropsychiatry Clin. Neurosci. 10, 453–455 (1998).
   PubMed Web of Science ®Google Scholar
• Mohr DC, Cox D, Epstein L, Boudewyn A. Teaching patients to self-inject: pilot study of a treatment for injection anxiety and phobia in multiple sclerosis patients prescribed injectable medications. J. Behav. Ther. Exp. Psychiatry 33, 39–47 (2002).
   PubMed Web of Science ®Google Scholar
• Davison K, Bagley CR. Schizophrenia-like psychoses associated with organic disorders of the central nervous system: a review of the literature. In: Current Problems in Neuropsychiatry. Herrington FA (Ed.). Headly, Kent, UK, 113–184 (1969).
   Google Scholar
• Feinstein A, du Boulay G, Ron MA. Psychotic illness in multiple sclerosis. A clinical and magnetic resonance imaging study. Br. J. Psychiatry 161, 680–685 (1992).
   PubMed Web of Science ®Google Scholar
• Ron MA, Logsdail SJ. Psychiatric morbidity in multiple sclerosis: a clinical and MRI study. Psychol. Med. 19, 887–895 (1989).
   PubMed Web of Science ®Google Scholar
• Schiffer RB, Babigian HM. Behavioral disorders in multiple sclerosis, temporal lobe epilepsy, and amyotrophic lateral sclerosis. Arch. Neurol. 41, 1067–1069 (1984).
   PubMed Web of Science ®Google Scholar
• Patten SB, Neutel CI. Corticosteroid-induced adverse psychiatric effects. Incidence, diagnosis and management. Drug Safety 22, 111–122 (2000).
   PubMed Web of Science ®Google Scholar
• Patten SB, Williams JVA, Petcu R, Oldfield R. Delirium in psychiatric in-patients. A case-control study. Can. J. Psychiatry 46, 162–166 (2001).
   PubMed Web of Science ®Google Scholar
• Bagert B, Camplair P, Bourdette D. Cognitive dysfunction in multiple sclerosis. Natural history, pathophysiology and management. CNS Drugs 16, 445–455 (2002).
   PubMed Web of Science ®Google Scholar
• Folstein MF, Folstein SE, McHugh PR. Mini-mental State Examination. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189–198 (1975).
   PubMed Web of Science ®Google Scholar
• Amato MP, Zipoli V. Clinical management of cognitive impairment in multiple sclerosis: a review of current evidence. Int. MS J. 10, 72–83 (2003).
   PubMedGoogle Scholar
• Plohmann AM, Kappos L, Ammann W et al. Computer assisted retraining of attentional impairments in patients with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 64, 455–462 (1998).
   PubMed Web of Science ®Google Scholar
• Solari A, Motta A, Mendozzi L et al. Computer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-blind controlled trial. J. Neurol. Sci. 222, 99–104 (2004).
   PubMed Web of Science ®Google Scholar
• Krupp LB, Christodoulou C, Melville P et al. Donepezil improved memory in multiple sclerosis in a randomized controlled trial. Neurology 63, 1579–1585 (2004).
   PubMed Web of Science ®Google Scholar
• Geisler MW, Sliwinski M, Coyle PK et al. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch. Neurol. 53, 185–188 (1996).
   PubMed Web of Science ®Google Scholar
• Lincoln NB, Dent A, Harding J et al. Evaluation of cognitive assessment and cognitive intervention for people with multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 72, 93–98 (2001).
   Web of Science ®Google Scholar
• Fisk JD, Pontefract A, Ritvo PG, Archibald CJ, Murray TJ. The impact of fatigue on patients with multiple sclerosis: 1. Frequency, patterns, and prediction. Can. J. Neurol. Sci. 21, 9–14 (1994).
   PubMed Web of Science ®Google Scholar
• Freal JE, Kraft GH, Coryell JK. Symptomatic fatigue in multiple sclerosis. Arch. Phys. Med. Rehabil. 65, 135–138 (1984).
   PubMed Web of Science ®Google Scholar
• Zifko UA. Management of fatigue in patients with multiple sclerosis. Drugs 64, 1295–1304 (2004).
   PubMed Web of Science ®Google Scholar
• Taus C, Solari A, D’Amico R et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database of Systematic Reviews (2004).
   Google Scholar
• Rossini PM, Pasqualetti P, Pozzilli C et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult. Scler. 7, 354–358 (2001).
   PubMed Web of Science ®Google Scholar
• Krupp LB. Fatigue in multiple sclerosis. Definition, pathophysiology and treatment. CNS Drugs 17, 225–234 (2003).
   PubMed Web of Science ®Google Scholar
• Frierson RL, Wey JJ, Tabler JB. Psychostimulants for depression in the medically ill. Am. Family Physician 43, 163–170 (1991).
   PubMed Web of Science ®Google Scholar
• Krupp LB, Coyle PK, Doscher C et al. Fatigue therapy in multiple sclerosis: results of a double-bind, randomized, parallel trial of amantadine, pemoline and placebo. Neurology 45, 1956–1961 (1995).
   PubMed Web of Science ®Google Scholar
• Zifko UA, Rupp M, Schwarz S, Zipko HT, Maida EM. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J. Neurol. 249, 983–987 (2002).
   PubMed Web of Science ®Google Scholar
• Rammohan KW, Rosenberg JH, Lynn DJ et al. Efficacy and safety of modafinil (Provigil®) for the treatment of fatigue in multiple sclerosis: a two centre Phase 2 study. J. Neurol. Neurosurg. Psychiatry 72, 179–183 (2002).
   PubMed Web of Science ®Google Scholar
• Pliskin NH, Hamer DP, Goldstein DS et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon β-1b. Neurology 47, 1463–1468 (1996).
   PubMed Web of Science ®Google Scholar
• Fischer JS, Priore RL, Jacobs LD et al. Neuropsychological effects of interferon β-1a in relapsing multiple sclerosis. Ann. Neurol. 48, 885–892 (2000).
   PubMed Web of Science ®Google Scholar
• Freo U, Pizzolato G, Dam M, Ori C, Battistin L. A short review of cognitive and functional neuroimaging studies of cholinergic drugs: implications for therapeutic potentials. J. Neural Transm. 109, 857–870 (2002).
   PubMed Web of Science ®Google Scholar
• Simpson D, Plosker GL. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder. CNS Drugs 18, 397–401 (2004).
   PubMed Web of Science ®Google Scholar